(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year. The new drug is part of the second generation of weight-loss pills under...

Pfizer Moves Forward With Once-Daily Weight-Loss Pill

NGN-401 is being evaluated in an early phase clinical trial which has been selected for the FDA’s START Pilot Program. The FDA has granted Regenerative Medicine Advanced Therapeutic Designation to Neurogene’s gene therapy NGN-401 for the potential treatment of Rett syndrome.1. “We appreciate the FDA’s ongoing commitment to...

Rett Syndrome Gene Therapy Adds RMAT Designation to the List

Conduit Pharmaceuticals Inc. announced that the company has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase...

Conduit Pharmaceuticals and AstraZeneca to Partner on Multiple Assets to Advance Potential First-in-Class Treatments

Today, a brief rundown of news from Merck & Co. and Cabaletta Bio, as well as updates from Intellia Therapeutics, Vertex Pharmaceuticals and Novartis that you may have missed. An experimental Merck & Co. drug aimed at the cancer immunotherapy target TIGIT has failed another clinical trial, the company said Thursday. Independent trial monitors advised Merck to stop a Phase 3 study testing a co-formulation of the medicine, vibostolimab, and its drug Keytruda in advanced small-cell lung cancer because treatment was unlikely to extend survival compared to an immunotherapy and chemotherapy regimen and was associated with higher rates of side effects, Merck said. The vibostolimab-Keytruda combination has already fallen short in studies for lung and skin cancer. — Ben Fidler.

Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study

Antiretroviral therapy (ART) has been a game-changer for people with HIV. But HIV is skilled at “hiding” and can reappear in the blood stream shortly after ART is stopped. That’s why NIAID and partners are investigating strategies to completely clear HIV from a person’s body, effectively curing them, or to reduce it to levels that can be suppressed by their own immune systems.

Broadly Neutralizing Antibodies Evaluated in Many HIV Cure Strategies

The US Sun

A SINGLE-dose nasal spray treatment could 'wash away' build ups of toxic proteins associated with Alzheimer’s disease from brain cells and improve memory, scientists say. The study - performed on mice - paves the way for new treatments against Alzheimer's and dementia, researchers at the University of Texas Medical Branch said.

Single-dose nasal spray ‘washes the brain’ of toxic Alzheimer’s proteins – paving the way for breakthrough treatment

Reuters

(Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's website showed on Wednesday.

US FDA approves Novartis' kidney disease drug

The first therapy that uses gene-editing is to be offered on the NHS in a “revolutionary breakthrough” for patients. It will be used as a potential cure for the blood disorder beta thalassaemia. Stem cells which make blood will be extracted, reprogrammed to correct the condition and returned...

First gene-editing therapy may cure blood disorder

shefinds

Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Characterized by tremors, stiffness, and difficulty with balance and coordination, the disease is primarily caused by the loss of dopamine-prod...

3 Supplements A Neuroscientist Swears By To Prevent Parkinson’s Disease: ‘Gives Your Brain The Raw Materials To Repair Itself’

Arthrogryposis–Renal Dysfunction–Cholestasis Syndrome (ARC Syndrome) is a rare genetic disorder that affects multiple systems in the body. Characterized by joint contractures, kidney problems, and liver issues, this condition presents significant challenges for those diagnosed. Caused by mutations in the VPS33B or VIPAR genes, ARC Syndrome is inherited in an autosomal recessive pattern. Symptoms often appear at birth or in early infancy, making early diagnosis crucial for managing the condition. Treatment focuses on alleviating symptoms and improving quality of life, as there is currently no cure. Understanding ARC Syndrome can help families and healthcare providers better support affected individuals.

20 Facts About Arthrogryposis–Renal Dysfunction–Cholestasis Syndrome

Everyday Health

Learn about eosinophilic esophagitis (EoE) and its symptoms, including chronic cough, treatment options, and diagnosis methods.

Can Eosinophilic Esophagitis Be the Reason Behind Your Chronic Cough?

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma. Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutch Cancer Center; member, the International Myeloma Working Group; assistant professor, Division of Hematology and Oncology, University of Washington, discusses key takeaways from the presentation he gave at an OncLive® State of the Science Summit™ on multiple myeloma, highlighting the disease’s evolving treatment paradigm.

Dr Banerjee on the Evolving Multiple Myeloma Treatment Paradigm

Pete Williams is one of few researchers in Sweden concentrating on glaukoma. The goal is an effective treatment, something that stops the degenerative process in the nerve cells of the eye. Pete Williams is the senior author of a new paper in Nature Communications on how deficiency of the enzyme...

Glaucoma Research Reveals Potential Gene Therapy Target

Two recent developments in Alzheimer’s disease research offer new hope for patients living with the disease, and their families. Among those, in June, Tiziana Life Sciences received Food and Drug Administration clearance to use intranasal foralumab in its first patient with moderate Alzheimer’s disease under the FDA’s expanded access investigational new drug program.

FDA clears nasal spray for moderate Alzheimer’s disease in first patient

Ohio State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

The Lantern

On Tuesday, licensed Ohio dispensaries began legally selling non-medical marijuana to consumers; however, the drug’s possession, growth and/or usage are still prohibited on Ohio State’s campus. Credit: Jefferee Woo/Tampa Bay Times/TNS [Original caption: Four citizen-led petitions with proposals to update Dallas’ charter hit the 20,000 valid signature threshold to make it on the Nov. 5 election ballot, including one that would ban police officers from arresting or citing people carrying less than four ounces of marijuana.] As of Tuesday, students 21 and older can now legally purchase marijuana in Ohio.

Dispensary sales of recreational marijuana began Tuesday; possession and usage still prohibited on Ohio State’s campus

David Cooper, MD, chief medical officer at AviadoBio, provided insight on a new study assessing AVB-101, an investigational gene therapy, as a potential treatment for patients with frontotemporal dementia. Frontotemporal dementia (FTD), a neurodegenerative disorder, is the result of damage to neurons in the frontal and temporal lobes of the...

Newly Initiated ASPIRE-FTD Trial Opens Door for Gene Therapy to Treat Frontotemporal Dementia

Multiple sclerosis (MS) is a disease that damages the nerves of the central nervous system. This damage disrupts nerve impulses and can lead to ataxia — a condition that affects coordination, balance, and speech. This article outlines the symptoms of ataxia. It also considers the prevalence of this condition...

What to know about ataxia in multiple sclerosis

(Reuters) - Servier Pharmaceuticals said on Tuesday the U.S. Food and Drug administration has approved the French drugmaker's treatment for a type of brain tumor, making it the first drug to get a U.S. approval for the condition.

US FDA approves Servier's brain tumor treatment

What is the esophageal sphincter? The esophageal sphincter is a muscular ring located at the junction of the esophagus and stomach. It plays a crucial role in digestion by controlling the passage of food and liquids. When functioning properly, it opens to allow food to enter the stomach and closes to prevent stomach contents from flowing back into the esophagus. This helps protect the esophagus from stomach acid and digestive enzymes. Problems with the esophageal sphincter can lead to conditions like acid reflux or gastroesophageal reflux disease (GERD). Understanding its function and importance can help maintain digestive health.

30 Facts About Esophageal Sphincter

First For Women

Healthcare company Roche said its trial-stage daily pill showed an average 6.1 percent weight loss in four weeks

A New Ozempic Pill? Roche Shakes Up the Weight Loss Drug Market With Promising Results: See The Data

NewsBreak

20 Facts About Pfizer Gene Therapy

Pfizer gene therapy represents a groundbreaking approach in modern medicine, aiming to treat genetic disorders at their root cause. But what exactly is gene therapy? Gene...

20 Facts About Pfizer Gene Therapy

Comments / 0